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Health Systems Section, School of Population Health, University of Auckland, Auckland, New ZealandA B S T R A C TObjective: To study the health impact on adult New Zealand patients
who switch from originator brand to generic venlafaxine. Methods: The
national pharmacy database was used to select patients using venlafaxine
for at least 6 months. Switchers and nonswitchers were identiﬁed, and
switch behavior was compared for a 12-month follow-up period. Change
in health service use following switching was also compared between
switchers and nonswitchers including use of the emergency depart-
ment, hospital, and specialist outpatient services over the same
period. Results: Approximately 12% of all originator brand users
switched to generic venlafaxine, at least half of whom continued to
use the generic throughout the follow-up period to August 1, 2012.
Almost 60% of new users of the generic venlafaxine, however, switched
to using the originator brand. Aside from a slight reduction in the use ofee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.02.020
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w Zealand.outpatient services among switchers, there were no signiﬁcant differ-
ences in health services use between switchers and nonswitchers for
either existing or new venlafaxine users. Conclusions: Although both
products remain fully subsidized and available, there is little incentive for
prescribers, pharmacists, or patients to switch to the less expensive generic
brand. If savings to the national New Zealand budget are to be realized,
additional policy measures should be implemented to minimize incentives
for multiple and reverse switching, and prescribers, as key opinion leaders,
could take the lead in promoting generics to their patients.
Keywords: generic, pharmaceutical pricing, substitution, venlafaxine.
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Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Depression affects more than 130 million people worldwide, with an
estimated lifetime prevalence of 10% to 15%. It carries a burden of
illness in itself and has been associated with greater rates of
mortality following myocardial infarction and stroke, and 20-fold
increases in the rate of death from suicide [1]. In addition, decreased
workplace productivity and psychosocial disability are key features
of depression [1]. The World Health Organization suggests that by
2030 depression will be the leading cause of disease burden, with the
disease affecting both developed and developing countries [1,2].
The lifetime risk for a major depressive illness in New Zealand
has been estimated to be approximately 25%, with a median age
of onset occurring in the early 1930s. It is expected that one in
four adults will experience an episode of major depression in his
or her lifetime [3]. Alongside psychosocial therapy, antidepres-
sant medicines form the mainstay of treatment, with selective
serotonin reuptake inhibitors (SSRIs) usually being the ﬁrst choice
of antidepressants. The advent of venlafaxine—a serotonin-
noradrenaline reuptake inhibitor—in the late 1990s offered anadditional treatment option in the antidepressant armory along-
side related SSRIs, despite higher rates of adverse events [4].
In New Zealand, the use of venlafaxine has generally been
reserved for “treatment-resistant” depression when a trial of at least
two other antidepressant medicines has not been successful [5,6].
The originator brand Efexor-XR was introduced in the New Zealand
market and subsidized by the government in early 2004, with special
restrictions requiring prescriptions to be initiated only by a psychia-
trist to limit usage while increasing experience with the medicine. In
2007, access was widened to include psychiatric registrars and
vocationally registered general practitioners and usage of the med-
icine increased. In mid-2011, a less expensive generic version of
venlafaxine (Arrow Venlafaxine XR) became available, subject to the
same prescribing and subsidy conditions as the originator brand [7].
No incentive, however, was given to pharmacists or prescribers to
encourage their patients to switch to the generic. Indeed, a reverse
incentive remains in place for pharmacists to both commence new
patients and continue existing ones on the more expensive origi-
nator brand because the pharmacy fee is made up in part of a
percentage of the base cost of the medicine.on behalf of International Society for Pharmacoeconomics and
conﬂicts of interest with regard to the content of this article.
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same pharmaceutical preparation rests on an assumption of
bioequivalence, that is, both medicines’ overall bioavailability
and maximum plasma concentrations being the same [8]. A
limited number of medicines are traditionally considered non-
interchangeable, either when bioequivalence has not been estab-
lished or the therapeutic index is narrow and the risk of toxicity
high. Despite this, successful substitution with generic cyclo-
sporine, long considered the archetypical noninterchangeable
medicine, has been recently reported in heart transplant patients
[9]. Establishing bioequivalence, however, does not guarantee
acceptance of the “same-but-different” generic medicine by
health professionals or patients, and concerns linger around the
interchangeability of generic medicines with their originator
counterparts [10,11]. Literature related to brand switching of SSRI
and serotonin-noradrenaline reuptake inhibitor medicines
focuses mainly on the market share of the brands, especially in
insurance settings with tiered-pricing plans that favor generic
equivalents for full subsidy [12]. Studies evaluating health out-
comes of SSRI brand switching are limited in number and
methodology. A US-based study reported increased health care
costs associated with therapeutic brand switching (changing from
one chemical entity to another), yet reported on brand-to-generic
switching of SSRIs as a whole. The switcher patients included in
this study also had signiﬁcantly different baseline scores for
depression than did their matched nonswitcher counterparts [13].
Available reviews of brand-to-generic switching of psychotropic
medicines include literature on a diverse range of medicines
including older and newer antidepressives, antipsychotics, and
antiepileptic medicines, blurring the picture on these distinct
pharmacological entities and contributing to misperceptions [14,15].
New Zealand’s Pharmaceutical Management Agency (PHARMAC)
is the agency responsible for making funding decisions regarding
which pharmaceutical preparations will be listed in the Pharma-
ceutical Schedule and thus provided largely free to all New Zea-
landers (outside of a co-payment of $5). Within a ﬁxed annual
budget, PHARMAC purchases around 2000 prescription preparations.
Evidence-based appraisals are used by PHARMAC in funding deci-
sions for novel medicines, as they are in similar agencies in England,
Canada, and Australia. In making funding decisions on generic
medicines, however, PHARMAC and its sister agencies must rely
on bioequivalence studies as submitted with product registration.
Although the bioequivalence and substitution of some med-
icines, for example, of originator brand aspirin with generic
aspirin, has long been accepted, substitution of medicines for
chronic illnesses with generic equivalents is viewed with suspi-
cion by patients as well as by pharmacists and doctors [16,17].
With the availability of a generic brand of venlafaxine in New
Zealand, PHARMAC has included both generic and originator brand
in the Schedule, rather than adopting a more stringent funding
decision that might have seen only generic venlafaxine fully
subsidized and the originator brand partially or unsubsidized. Over
time, use of the generic brand would be expected to increase
through the use of venlafaxine by new patients as well as through
incidental switching from originator to the generic brand (known to
occur for risperidone, olanzapine, and quetiapine at least) [18].
It is the patients using the generic option in a setting of price
neutrality who offer an opportunity to evaluate the consequences
of venlafaxine brand switching, with the aim of identifying oppor-
tunities or risks of brand switching within the New Zealand context.Methods
A retrospective study using the national health and pharmacy
claims data sets was undertaken of all adult patients in NewZealand using venlafaxine during the period from February 1,
2011, to August 1, 2013.
Data Sources
Prescription records are kept in a centralized government data-
base, the “PHARMS data set,” and form the basis for reimburse-
ment to pharmacies for the dispensing of prescription medicines
and service provision. In addition, all contacts with the public
health sector made by a patient are documented within a number
of other databases held by the Ministry of Health. The National
Minimum Dataset is a national collection of public and private
hospital discharge information, including coded clinical data for
inpatients and day patients, whereas the National Non-Admitted
Patients Collection information includes event-based purchase
units of medical and surgical outpatient events and visits to the
emergency department (ED). The Mortality Collection records the
underlying cause of death for all deaths registered in New
Zealand. Linkage of these data sets via an encrypted National
Health Index has been validated and is the basis of many New
Zealand health services studies [19].
Patients’ demographic characteristics that were extracted
include age, sex, ethnicity, and home address. An individual’s
home address is further associated with a place of domicile index
—the New Zealand small-area index of relative socioeconomic
deprivation (“NZDep”), which is derived from census data. The
NZDep is a 10-point scale, with an index of 10 indicating the area
of domicile is lived in by the least socially and materially well-off
people. It is widely used in health research as well as by planners
and for the allocation of health funds in New Zealand [20], and
was also extracted for inclusion in the analysis.
Information on the cost and availability of venlafaxine was
sourced from publicly accessible information from PHARMAC
Annual Reports and the Pharmaceutical Schedule. Adverse reac-
tion reports were obtained from the national Centre for Adverse
Reactions Monitoring (CARM).
Cohorts
On August 1, 2011, generic venlafaxine became available for
prescribing with full subsidy, although advance notice of its
availability had been given to prescribers and pharmacies for at
least 6 months (to allow for a period of stabilization of both drug
choice and dosage) and in keeping with New Zealand guidelines
[6]. Thus, from this date onward, it was anticipated that there
would be new users of both the originator and the generic brands
as well as existing users of the originator brand. Accordingly,
study cohorts were constructed using the pharmacy data set to
identify both new users of venlafaxine (either brand) and patients
using originator venlafaxine continuously for at least 6 months
before the introduction of the generic on August 1, 2011 (see
Fig. 1). Adult patients who received a continuous supply of
originator venlafaxine (prescriptions dispensed covering at least
168 days) in the 6 months preceding August 1, 2011, formed the
“existing user” cohort (n ¼ 10,212). Two further cohorts were
constructed from patients using venlafaxine for the ﬁrst time
between August 1, 2011, and July 31, 2012, and for 6 successive
months: one of new users of the originator venlafaxine (n ¼ 3819)
and another for the generic venlafaxine (n ¼ 201).
Switch dates were recorded for all switchers and the time
taken to switch calculated (days), this being the difference from
the start date in the case of new users and from the policy date of
August 1, 2011, in the case of existing users. Nonswitcher patients
were assigned an “index date” upon which outcomes preindex
and postindex date could be measured. Assigned index dates
proportionally matched switch dates of switchers, and were
randomly allocated. Follow-up was conducted for a period of 12
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Fig. 1 – Construction of venlafaxine study cohorts.
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ers) in the existing user cohort, and for 6 months in the new user
groups. The number of switches was counted for each patient,
and speciﬁcally the rate of switching back to a previous brand
within 14 days—a “switch-back”—was noted.
Data Management and Analysis
Baseline characteristics were examined for any statistical differ-
ences using t tests for continuous data and chi-square test for
categorical data where appropriate. Prescription records were
used to identify baseline comorbidities, as well as any change
in the number of antidepressant medicines used per patient.
Different disease score methods have been described; however,
no “criterion standard” has yet been agreed on [21–23]. Most use
International Classiﬁcation of Diseases, Ninth Revision or other diag-
nostic codes, whereas a few use medications as the primary
source of information, the so-called chronic disease score,
wherein prescribed medicines are associated with disease
groups and used to inform costs or outcomes—with or withoutadditional weighting for the relative severity of disease [24–28].
This study used an unweighted chronic disease score, using the
World Health Organization’s “Anatomical Therapeutic Chemical
Classiﬁcation System,” to assess all unique chronic medicines
(excluding depression) dispensed to each patient. In addition, a
simpliﬁed score of the number of distinct prescription medicines
in the year preceding the index date was used because this has
been suggested to be as effective in predicting future health care
utilization as using a weighted chronic disease score [29,30].
Correlation with switch status was examined for demographic
variables.
Medical encounters were identiﬁed from national data collec-
tions and included unplanned visits to a hospital (either to the ED
or admission as an inpatient) and referrals to outpatient special-
ist clinics. Health outcome variables are presented as counts/
person (e.g., number of visits to the ED per person per time
period). In addition, a composite outcome of all visits (i.e.,
number of visits to ED þ inpatient þ outpatient per person
per time period) was computed. Because data were collected at
an individual patient level, paired tests of signiﬁcance were
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as signiﬁcant. Differences in the number of health events for both
the preindex and postindex periods were used to determine the
change in rate of utilization, with 95% conﬁdence limits pre-
sented for each outcome. Difference-in-differences values are
presented for the outcomes in switchers versus nonswitchers.
Adverse reaction data were obtained from the national CARM.
The national deaths register was also examined for 1 year
following the index or switch date to identify any of the study
participants.
Data were managed and statistical analyses conducted using
Microsoft Excel (Microsoft Corporation, Redmond, WA) and SPSS
(version 18; IBM Software New York, NY). This study was
approved by the University of Auckland Human Ethics Commit-
tee, and permission to access patient data was received from the
Ministry of Health of New Zealand.Results
Demographic characteristics of the Cohorts
In the ﬁrst 6 months following the introduction of generic
venlafaxine in the PHARMAC Schedule, uptake of the generic
brand was low, with only 201 new generic users (5%) meeting the
inclusion criteria compared with 3819 new users of originator
venlafaxine. (Note that this does not necessarily reﬂect all users
of venlafaxine in New Zealand, rather only those for whom a
continuous 6-month supply could be identiﬁed from the PHARMS
database.) Table 1 presents the characteristics of the cohorts, and
Table 2 presents the characteristics of switchers and
nonswitchers.
Nonswitchers were slightly older than switchers in both new
user cohorts, whereas a higher proportion of switchers lived in
areas of greater deprivation (NZDep 7–10). For new users of
generic venlafaxine, the apparent difference in deprivation index
did not reach statistical signiﬁcance, possibly because of the
small size of the group. Venlafaxine was used as monotherapy
slightly less in existing nonswitcher users than in switchers, but
equally in the new user cohorts.
The correlation of demographic factors with switch status was
examined; however, individual correlations were weak, with the
variables only minimally accounting for the likelihood to switch.
Regression analysis revealed a Nagelkerke R2 of 0.008 for the
predictors of demographic characteristics and monotherapy andTable 1 – Key demographic characteristics of the
three venlafaxine cohorts*.
Characteristic Existing
originator
users
New
originator
users
New
generic
users
Number 10,212 3819 201
Sex: male (%) 35 36 41
European (%) 88 86 86
Maori and Paciﬁca (%) 6 7 7
Living in area of high
socioeconomic
deprivation (%)
41 41 43
Mean age (y) 49 45 44
* Existing originator users had been using originator brand venla-
faxine for at least 6 mo before the policy date (August 1, 2011),
whereas new users had not been exposed to venlafaxine (either
brand) before that date.comorbidity (i.e., the predictors accounted for o1% of variance.)
Monotherapy was the only predictor indicating likelihood to
switch (odds ratio 0.80 for not switching [95% conﬁdence interval
0.69–0.92]).Switching Patterns
Switching between available brands was noted for a period of up
to 1 year from August 1, 2011. Of the 10,212 existing originator
brand users, most of the patients continued using the originator
brand (“nonswitchers”), with only 12% switching to the generic
(see Table 3). Similarly, most of the new originator brand users
(88%) did not switch. Conversely, a large proportion (almost 60%)
of the generic new users made at least one brand switch.
Prescriptions for venlafaxine are generally written for a 3-
month period, usually in 1-month lots. The time to make the ﬁrst
switch was similar for both originator brand user cohorts, with a
switch ﬁrst occurring around 6 months from August 1, 2011. New
generic users switched slightly earlier on average at 4 months
from commencement.
In both originator brand switcher groups, more than half
made a single switch; that is, they switched to generic venlafax-
ine and continued using it throughout the following year (see
Table 3). Forty-ﬁve of the switchers (3.8%) from the existing user
group, however, made a switch back to originator venlafaxine
within 14 days of their ﬁrst switch.
Twenty-four percent of existing switchers and 36% of new
originator brand switchers returned to using the previously used
brand (generic-to-originator). Among the new generic user
switchers, most (71%) switched from generic to originator brand.
Among all switchers, more than 1 in 10 patients made multiple
(Z3) switches.Pharmacy and Prescriber Loyalty
Most patients included in this study used a single prescriber
(range 93%–97%). Among all switchers combined (n ¼ 1742), 79%
used a single pharmacy, compared with 94% of nonswitchers. A
statistically signiﬁcant but weak correlation exists between
switching and number of pharmacies used (P ¼ 0.000; Pearson
r ¼ 0.14). The maximum number of pharmacies used by a single
patient was 13.
In addition, 30% of all pharmacies never dispensed generic
venlafaxine between August 1, 2011, when it became available,
and January 31, 2014.Health Outcomes
The ﬁndings observed for existing originator brand users are
summarized in Table 4 and for new users in Table 5. There were
too few new users of generic venlafaxine to detect differences
between switchers and nonswitchers and hence the ﬁndings are
not presented.Health services use
For existing originator users, there were no signiﬁcant differences
between switchers and nonswitchers in all outcome measures
except the lower use of specialist outpatient services over 1 year
made by switchers (0.6 less visits/person). No differences in
health services use between switcher and nonswitcher new
originator users were found. For all contacts made with the
health system combined (composite outcome of ED use, hospital-
izations, and outpatient specialist services), no difference could
be found between switchers and nonswitchers at 6 months, for
either new or for existing users of the originator brand.
Table 2 – Key demographic characteristics of switchers vs. nonswitchers by cohort*.
Characteristic Existing originator users New originator users New generic users
Nonswitcher
(n ¼ 9036)
Switcher
(n ¼ 1176)
Nonswitcher
(n ¼ 3371)
Switcher
(n ¼ 448)
Nonswitcher
(n ¼ 83)
Switcher
(n ¼ 118)
Proportion (%) 88.5 11.5 88.3 11.7 41.3 58.7
Sex: male (%) 34.6 37.3 36.3 35.0 38.6 42.4
European (%) 87.7 87.7 85.9 84.2 83.1 87.3
Maori and Paciﬁc peoples (%) 6.0 6.7 6.9 8.5 7.2 5.9
Living in area of high
socioeconomic deprivation (%)
40.4 42.3 39.7† (P ¼ 0.007;
r ¼ 0.04)
46.2 36.1 47.0
Mean age (y) 48.9 48.4 45.2† (P ¼ 0.001;
r ¼ –0.05)
42.9 46.8† (P ¼ 0.012;
r ¼ –0.18)
41.3
Median comorbidity count 2 2 1 1 1 1
Venlafaxine as monotherapy (%) 67.5† (P ¼ 0.001;
r ¼ 0.03)
72.5 74.9 73.9 81.9 73.7
* Existing originator users had been using originator brand venlafaxine for at least 6 mo before the policy date (August 1, 2011), whereas new
users had not been exposed to venlafaxine (either brand) before that date.
† Signiﬁcant vs. switcher. A switcher is a patient changing from one brand to a second brand (either originator-to-generic or generic-to-
originator). Nonswitchers did not make a change in brand.
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New Zealand’s national CARM receives reports from doctors,
pharmacists, patients, and the pharmaceutical industry. Before
the introduction of generic venlafaxine, on average 35 reports
were received by CARM annually for originator venlafaxine.
During the year 2011 immediately following the introduction of
generic venlafaxine, no reports of adverse events were received
related to a change in brand, whereas there were 33 other adverse
events reported related to venlafaxine in general. In 2012, of the
29 reports received, 4 related to a brand switch, and in 2013, 2 out
of 16 reports were brand-switch related. None of the switch-
related reports, however, was for loss in therapeutic response.Deaths
The rate of death among existing originator users was the same
for nonswitchers (0.02) and switchers (0.02) when followed up for
at least 1 year after the index date. For new users of originator
venlafaxine, the rates were 0.01 and 0.004 for nonswitchers and
switchers, respectively, and for new generic brand users was 0.01
for both nonswitchers and switchers.Discussion
Uptake of generic venlafaxine among new users in New Zealand
is low at 5%, and minimal switching to the generic occurs.Table 3 – Switching patterns of the three venlafaxine coh
Measure Existing originator us
Number of switchers (proportion) 1172 (11.5%)
Days to ﬁrst switch, mean  SD 189  129
Number (%) making a single switch 712 (60)
Proportion switching back within 14 d 45 (3.8%)
Number (%) making a second switch† 290 (24)
Number (%) making Z3 switches† 129 (11)
* Existing originator users had been using originator brand venlafaxine fo
users had not been exposed to venlafaxine (either brand) before that d
† At any time up to 1 y after the ﬁrst switch.Approximately 12% of the 14,031 originator brand users in this
study switched to generic venlafaxine, whereas approximately
60% of the 201 generic users switched to the originator brand (i.e.,
“reverse switching”). No net effect on health service use, how-
ever, could be found for either new or existing originator-to-
generic brand switcher patients compared with nonswitchers.
Some 4% of the patients switched back to the originator brand
within 2 weeks of switching, suggesting a possible adverse
response to the generic brand. Despite being unable to provide
a precise reason for a switch-back, such a rate is of the order
expected with any medicine that may equally be due to the
excipients in the formulation, and no reports of loss in thera-
peutic effect were received by the adverse reactions monitoring
center, CARM, during the study years.
The ﬁndings of this study are consistent with those of similar
studies from New Zealand evaluating the effects of lamotrigine
and risperidone brand switching where, despite patterns of
multiple switches among patients, no adverse effects were
evident [31,32]. Further reports related to venlafaxine include a
report of therapeutic drug monitoring of venlafaxine in Germany
among 35 patients that found no difference in serum concen-
trations between originator brand and generic formulations [33],
and another bioavailability study among volunteers where no
difference between originator and generic formulations was
found [34]. Another study determined that the maximum plasma
concentration between different venlafaxine preparations was
initially (up to 6 hours) not the same, yet at steady state, noorts*.
ers New originator users New generic users
448 (11.7%) 118 (58.7%)
175  110 121  98
230 (51) 84 (71)
1 (0.2%) 0
163 (36) 16 (14)
54 (12) 18 (15)
r at least 6 mo before the policy date (August 1, 2011), whereas new
ate.
Table 4 – Health outcomes for switchers vs. nonswitchers: Existing users of originator venlafaxine.
Outcome measure Post-pre difference:
Nonswitchers*
(n ¼ 9036)
Post-pre difference:
Switchers* (n ¼ 1176)
Difference-in-
differences
(95% CI)†
Signiﬁcance
(P)
Change in visits to the ED per person (30 d) 0.00 0.01 0.01 (–0.01 to 0.03) 0.24
Change in visits to the ED per person
(6 mo)
0.00 0.04 0.04 (–0.02 to 0.1) 0.15
Change in hospital admissions per person
(30 d)
0.00 0.01 0.01 (–0.01 to 0.03) 0.31
Change in annual number of hospital
admissions per person
0.00 0.02 0.02 (–0.05 to 0.1) 0.65
Change in use of specialist outpatient
services per person (30 d)
–0.01 –0.03 –0.02 (–0.07 to 0.03) 0.47
Change in annual use of specialist
outpatient services (visits per person)
–0.17 –0.77 –0.6 (–1.2 to –0.05) 0.03
Change in composite outcome (6 mo)‡ –0.06 –0.33 –0.28 (–0.6 to 0.01) 0.06
Change in number of unique prescriptions
per person per year
0.00 0.04 –0.04 (–0.4 to 0.4) 0.99
CI, conﬁdence interval; ED, emergency department.
* A switcher is a patient changing from originator to generic venlafaxine. Nonswitchers did not make a change in brand.
† Analysis using propensity score matching among the existing user group was also conducted (n ¼ 1176 matched pairs), producing the same
overall ﬁndings.
‡ Composite outcome ¼ all contacts made with the health system combined (ED use, hospitalizations, and outpatient specialist services).
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found that rates of discontinuation were similar for brand and
generic brand antidepressants including venlafaxine but that
short-term health care costs and pharmacy costs were lower in
new generic users [36].
Although consistent with the ﬁndings of the limited available
research on venlafaxine, the present study extends the existing
literature in several important ways. The number of patients
included in this study—some 1600 switcher and 14,000 non-
switcher patients—greatly exceeds that in bioavailability studies,
which often also only use healthy volunteers, adding certainty to
the ﬁndings. Also, in the context of New Zealand, this study
capitalizes on national policies that, when enacted, affect the
total population. When a change is made in the New Zealand
Pharmaceutical Schedule, such as that of venlafaxine, conditions
of a natural experiment exist, whereby the total affected pop-
ulation (users of venlafaxine) is exposed to the same intervention
(availability of generic venlafaxine) outside of the researcher’s
control: a controlled clinical trial would struggle to achieve
similar parameters.Table 5 – Health outcomes for switchers vs. nonswitcher
Outcome measure Post-pre
difference:
Nonswitchers*
(n ¼ 3371)
Change in visits to the ED per person (30 d) 0
Change in visits to the ED per person (6 mo) 0.03
Change in hospital admissions
per person (6 mo)
0.01
Change in use of specialist outpatient
services per person (6 mo)
0.07
Change in composite outcome (6 mo)† 0.23
CI, conﬁdence interval; ED, emergency department.
* A switcher is a patient changing from originator to generic venlafaxine
† Composite outcome ¼ all contacts made with the health system combDespite these strengths, there are a number of important
limitations that need to be considered when interpreting the
ﬁndings of the present study. As an observational study using
health care databases, randomization is not possible, making the
evaluation of potential confounders all the more important
[37,38]. The intergroup variability between switchers and non-
switchers found in this study was limited to a single variable
each (out of seven measures) among existing originator and new
generic users and two variables among new originator users.
Correlation of these variables with the likelihood to switch was so
low as to be negligible (see Table 2). Misclassiﬁcation or incom-
pleteness of data cannot be ruled out in these databases; how-
ever, the PHARMS database is an administrative database used
for reimbursements to the pharmacy and, together with the
special authority (SA) requirements, improves the reliability of
the data. This study has been able to focus only on originator-to-
generic brand switching and not on generic-to-originator brand
switching because of the low uptake of generic venlafaxine in
new users. Retrospective sample size calculations indicate that
for a power of 80% a population size of around 400 would bes: New users of originator venlafaxine.
Post-pre difference:
Switchers* (n ¼ 448)
Difference-in-
differences
(95% CI)
Signiﬁcance
(P)
–0.02 –0.01 (–0.05 to 0.02) 0.56
0.1 0.08 (–0.002 to 0.2) 0.17
0.02 0.01 (–0.06 to 0.09) 0.75
0.2 –0.13 (–0.48 to 0.22) 0.47
0.19 –0.04 (–0.4 to 0.4) 0.85
. Nonswitchers did not make a change in brand.
ined (ED use, hospitalizations, and outpatient specialist services).
Fig. 2 – Price of 28 days’ supply of 75 mg venlafaxine in New Zealand.
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venlafaxine users [39].
A follow-up period of 12 months was chosen in the case of
existing users, being a period long enough to detect any health
outcomes consequent to switching, and to accommodate any
seasonality variation. In the case of new users, the difference-in-
differences comparison could be made for only up to 6 months
because the inclusion criteria required patients not taking ven-
lafaxine at any time in the preceding 12 months and for at least 6
months (only) from the policy index date.
Due in part to changes in the method of funding at the
primary care level, data on individual patient-general practitioner
visits were not captured at a central level during the study years.
This means that data are not available to indicate contacts made
with either the dispensing pharmacy or the general practice in
relation to brand switches. It is possible that a patient would seek
reassurance from both the pharmacist and the primary care
physician if he or she considered a change in venlafaxine brand
was problematic. This study uses two variables—the switch-back
rate and the number of unique prescriptions/year—as an indirect
measure of this effect based on the knowledge that up to 70% of
all visits to the doctor in New Zealand result in a prescription
being written [40]. Despite the fact that a dispensed medicine
does not necessarily mean that the medicine has been taken,
either as intended or at all, pharmacy databases are accepted as a
close approximation of medicine use [37].Implications
Switching to generic venlafaxine in this study occurred without
any detectable increase in health services use, and so apparently
did not impose any additional health costs. Considerable savings
could have been made had the price of generic venlafaxine been
negotiated to 50% of the originator on introduction and incen-
tives to switch created. Approximately NZ $2 million (75 mg
monthly dosage) in the ﬁrst year might have been saved with
complete switching to generic venlafaxine at 2012 prices (see
Fig. 2). It is thus worth exploring the barriers to switching, or lack
of incentives to switch, within the context of this study.
At the introduction of generic venlafaxine, no incentive
existed to promote its use. Despite this, 1 in 10 patients switched
from originator to generic venlafaxine. Before September 2013,
there was no incentive for either the doctor or the patient to
choose which brand of venlafaxine to use because both brandswere subject to the same SA approval process. Since late 2013,
however, generic venlafaxine no longer requires an SA for
prescribing and subsidy, and this should act as an incentive for
doctors to prescribe generic venlafaxine. Existing patients can
continue to receive the originator brand fully funded if their
doctor renews the SA (given for 2-year periods), and because
direct-to-consumer advertising is permitted in New Zealand, the
supplier of the originator brand encourages patients to insist on
this [41]. A similar situation existed in Sweden whereby the
absence of demand-side activities to encourage the use of generic
venlafaxine led to no change in utilization. An increase in the use
of venlafaxine, however, was observed when prescribing of
duloxetine was restricted, and near-complete generic prescribing
of venlafaxine was achieved in 2011 once subsidy of the origi-
nator brand was removed in 2009 [42]. This removal of the
subsidy in Sweden tested “brand worship” [43], whereas New
Zealand has continued to fully subsidize the originator brand,
leaving patients (in theory) with the choice of brand. Belgium too
instituted preferential reimbursement for generic SSRIs, yet
found that marketing strategies—including the introduction of
pseudogenerics and prescribing and consumer brand loyalty—
threatened the economic gains made by the policy [44].
Pharmacies in New Zealand are contracted by the District
Health Boards to provide services to patients, including dispens-
ing medicines for which pharmacies are reimbursed. At the time
of this study, reimbursements for medicines dispensed were
subject to a complex formula, but which in essence were
calculated as a proportion (4%) of the price as gazetted in the
PHARMAC Schedule [45]. Thus, a disincentive to switch patients
to the less expensive generic venlafaxine now exists for phar-
macy owners. This is reﬂected in the ﬁndings that 30% of the
pharmacies in this study did not dispense generic venlafaxine at
all, a stance PHARMAC has cautioned pharmacy owners against
[5]. Whether it is the pharmacy or the patient making a choice to
switch or not is unclear; however, it is clear that 60% of generic
users switched (or were switched) to the originator brand.
Pharmacists are within the bounds of New Zealand law if they
switch brands provided they inform the patient of the change;
the patient’s consent, although implied, is not speciﬁcally
required, and the prescribing doctor need not be informed either
[46]. With the incentive remaining in favor of dispensing the
originator brand, and the law facilitating both an originator-to-
generic and generic-to-originator switch, it is likely that the use
of generic venlafaxine will be limited until differences in the
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 4 6 – 6 5 4 653price are decreased and speciﬁc measures are taken to enco-
urage generic prescribing and to counter direct-to-consumer
advertising. It may be that additional policy measures should
be implemented to minimize incentives for multiple switching
and reverse switching, and prescribers, as key opinion leaders,
could take the lead in promoting generics to their patients.
In summary, this study provides evidence for the safety of
originator-to-generic venlafaxine switching, yet raises issues
regarding the roles of the patient, prescriber, and pharmacist in
brand switching within the New Zealand context. Monitoring
around the time of the switch may be prudent [47], but probably
unwarranted if health practitioners and patients are adequately
engaged in the switch process. Speciﬁc measures will need to be
taken to increase the use of generic venlafaxine if potential
savings are to be made to New Zealand’s pharmaceutical
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